Alison J. Moskowitz

Alison Moskowitz practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Alison Moskowitz's NPI, 1881850626, was assigned on July 31, 2008. Alison Moskowitz graduated from Albert Einstein College of Medicine in 2003. Alison Moskowitz holds New York license 235165.

Alison Moskowitz's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Alison Moskowitz's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Hematology Lymphoma Group. Dmand AI also links Alison Moskowitz to 1 more home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Alison Moskowitz practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Alison Moskowitz's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Alison Moskowitz is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Alison Moskowitz's licenses on file in 6 states: New York, Florida, New Jersey, Connecticut, Pennsylvania and Oregon.

Dmand AI lists chronic leukemia and lymphoma among the conditions Alison Moskowitz treats.

CMS data shows 761 Medicare services from Alison Moskowitz across 7 procedure codes in 2024, for 266 Medicare patients. Medicare paid $74,515 for them.

CMS counts 266 Medicare patients who saw Alison Moskowitz in 2024. The largest group is 75 to 84, with 108 patients. 75% of them have high cholesterol, and 66% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Alison Moskowitz's median patient age at 72, with 49% women.

In 2024, Alison Moskowitz wrote 546 Medicare Part D claims for 79 patients. 74% of them were for generic drugs. CMS names the drug for 340 of them, across 14 drugs with 11 or more claims each, at $2,446,457 in total drug cost. In 2023, CMS named 232 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Alison Moskowitz for performance year 2024, reported as part of a group. Alison Moskowitz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Alison Moskowitz as offering telehealth.

Dmand AI links 120 papers to Alison Moskowitz, published from 2007 to 2025. 2018 was the busiest year, with 10. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Hodgkin Disease and Brentuximab Vedotin. Alison Moskowitz has published most often in Blood Adv. Alison Moskowitz's most frequent co-authors are Steven M. Horwitz, MD, Craig H. Moskowitz, MD and Ariela Noy, MD.

Dmand AI links Alison Moskowitz to 14 clinical trials, 9 of them phase 2 studies. 11 are still active or recruiting. Conditions studied include Lymphoma, Hodgkin Disease and Sezary Syndrome. Memorial Sloan Kettering Cancer Center sponsors the most, 10.

CMS Open Payments shows 88 general payments to Alison Moskowitz from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Seagen Inc. paid the most, $50,671. It also lists 2 research payments totaling $1,270 in 2025.

Alison Moskowitz graduated from Albert Einstein College of Medicine in 2003. Alison Moskowitz is a member of ASCO.

Alison Moskowitz is in network with 13 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.